Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6621 in metastatic castration-resistant prostate cancer
NL-OMON61272Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selumetinib in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events and serious adverse events, Discontinuation due to toxicity and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
selumetinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON61272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61272.